GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viva Biotech Holdings (HKSE:01873) » Definitions » Current Ratio

Viva Biotech Holdings (HKSE:01873) Current Ratio : 1.32 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Viva Biotech Holdings Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Viva Biotech Holdings's current ratio for the quarter that ended in Dec. 2023 was 1.32.

Viva Biotech Holdings has a current ratio of 1.32. It generally indicates good short-term financial strength.

The historical rank and industry rank for Viva Biotech Holdings's Current Ratio or its related term are showing as below:

HKSE:01873' s Current Ratio Range Over the Past 10 Years
Min: 0.73   Med: 3.13   Max: 15
Current: 1.32

During the past 8 years, Viva Biotech Holdings's highest Current Ratio was 15.00. The lowest was 0.73. And the median was 3.13.

HKSE:01873's Current Ratio is ranked worse than
77.99% of 1545 companies
in the Biotechnology industry
Industry Median: 3.78 vs HKSE:01873: 1.32

Viva Biotech Holdings Current Ratio Historical Data

The historical data trend for Viva Biotech Holdings's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viva Biotech Holdings Current Ratio Chart

Viva Biotech Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial 15.00 4.56 2.14 0.73 1.32

Viva Biotech Holdings Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.14 1.73 0.73 0.69 1.32

Competitive Comparison of Viva Biotech Holdings's Current Ratio

For the Biotechnology subindustry, Viva Biotech Holdings's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viva Biotech Holdings's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's Current Ratio distribution charts can be found below:

* The bar in red indicates where Viva Biotech Holdings's Current Ratio falls into.



Viva Biotech Holdings Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Viva Biotech Holdings's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=2221.375/1678.052
=1.32

Viva Biotech Holdings's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=2221.375/1678.052
=1.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Viva Biotech Holdings  (HKSE:01873) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Viva Biotech Holdings Current Ratio Related Terms

Thank you for viewing the detailed overview of Viva Biotech Holdings's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Viva Biotech Holdings (HKSE:01873) Business Description

Traded in Other Exchanges
Address
735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318
Viva Biotech Holdings is an integrated drug discovery platform. The company's operating segment includes Drug discovery services and Contract Development Manufacture Organisation (CDMO) and commercialisation services. It generates maximum revenue from the Contract Development Manufacture Organisation (CDMO) and commercialisation services segment. The Contract Development Manufacture Organisation ("CDMO") and commercialisation services segment includes contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations.
Executives
Mao Chen Cheney 2101 Beneficial owner
Wu John Jiong 2201 Interest of corporation controlled by you
Fenghe Harvest Ltd 2101 Beneficial owner
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Mao Jun 2501 Other
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
Zhou Min 2202 Interest of your spouse
Intertrust (singapore) Ltd. 2301 Trustee
Z&m International Holdings Limited 2201 Interest of corporation controlled by you
Zhang And Sons Limited 2101 Beneficial owner

Viva Biotech Holdings (HKSE:01873) Headlines

No Headlines